Autopsy report · NCT00134667
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Cause of deathNo reason given
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 3 years 7 months before it stopped.
- 360 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Eyetech Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Photodynamic Therapy (PDT) with Visudyne (verteporfin); Macugen (pegaptanib sodium)
- Participants
- 360
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.